Literature DB >> 16353984

Quantifying crystal form content in physical mixtures of (+/-)-tartaric acid and (+)-tartaric acid using near infrared reflectance spectroscopy.

Paul E Luner1, Aditya D Patel.   

Abstract

The objective of this study was to use diffuse reflectance near infrared spectroscopy (NIRS) to determine racemic compound content in physical mixtures composed primarily of the enantiomorph and to assess the error, instrument reproducibility and limits of detection (LOD) and quantification (LOQ) of the method. Physical mixtures ranging from 0 to 25% (+/-)-tartaric acid in (+)-tartaric acid were prepared and spectra of the powder samples contained in glass vials were obtained using a Foss NIRSystems Model 5000 monochrometer equipped with a Rapid Content Analyzer scanning from 1100 to 2500 nm. A calibration curve was constructed by plotting (+/-)-tartaric acid weight percent against the 2(nd) derivative values of log (1/R) vs lambda at a single wavelength, normalized with a denominator wavelength (1480 nm/1280 nm). Excellent linearity was observed (R(2)=0.9999). The standard error of calibration (SEC) was 0.07 and the standard error of prediction (SEP) for the validation set was 0.11. Instrument and method errors for samples in the 2% composition range ((+/-)-tartaric acid in (+)-tartaric acid) were less than 1% RSD and 3% RSD, respectively. The practical LOD and LOQ were 0.1% and 0.5%, respectively, and comparable to the calculated LOD and LOQ. These studies show that NIRS can be used as a rapid and sensitive quantitative method for determining racemate content in the presence of the enatiomerically pure crystal in the solid-state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353984      PMCID: PMC2750538          DOI: 10.1208/pt060235

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  13 in total

1.  Quantifying crystalline form composition in binary powder mixtures using near-infrared reflectance spectroscopy.

Authors:  P E Luner; S Majuru; J J Seyer; M S Kemper
Journal:  Pharm Dev Technol       Date:  2000       Impact factor: 3.133

2.  Determination of enantiomeric composition of ibuprofen in bulk drug by proton nuclear magnetic resonance spectroscopy with a chiral lanthanide chelate.

Authors:  G M Hanna
Journal:  J Pharm Biomed Anal       Date:  1997-08       Impact factor: 3.935

3.  Simultaneous quantification of an enantiomer and the racemic compound of ibuprofen by X-ray powder diffractometry.

Authors:  N V Phadnis; R Suryanarayanan
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

4.  Optimisation of sample presentation for the near-infrared spectra of pharmaceutical excipients.

Authors:  W L Yoon; R D Jee; A C Moffat
Journal:  Analyst       Date:  1998-05       Impact factor: 4.616

5.  Evaluation of key sources of variability in the measurement of pharmaceutical drug products by near infrared reflectance spectroscopy.

Authors:  M W Borer; X Zhou; D M Hays; J D Hofer; K C White
Journal:  J Pharm Biomed Anal       Date:  1998-08       Impact factor: 3.935

6.  Effects of grinding and humidification on the transformation of conglomerate to racemic compound in optically active drugs.

Authors:  S Piyarom; E Yonemochi; T Oguchi; K Yamamoto
Journal:  J Pharm Pharmacol       Date:  1997-04       Impact factor: 3.765

7.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview.

Authors:  D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

8.  Commonly used chiral drugs: a survey.

Authors:  J S Millership; A Fitzpatrick
Journal:  Chirality       Date:  1993       Impact factor: 2.437

9.  Effects of configuration around the chiral carbon atoms on the crystal properties of ephedrinium and pseudoephedrinium salicylates.

Authors:  S P Duddu; D J Grant
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

10.  (+-)-Tartaric acid.

Authors:  Paul E Luner; Aditya D Patel; Dale C Swenson
Journal:  Acta Crystallogr C       Date:  2002-05-21       Impact factor: 1.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.